But overexpression of EGFR and HER2/Neu in primary breast cancer is reported to be 0.8-14 and 15-20% respectively, whereas 40-98% of the primary breast tumours show enhanced EpCAM levels [20, 22]. This evidence concerns the gene ERBB2 and breast cancer.